Perlmutter Cancer Center

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Relapsed Acute Lymphoblastic Leukemia (all) Or Lymphoblastic Lymphoma (ll)
• Age: Between 1 years - 30 years
• Gender: Male or Female

• Other Inclusion Criteria:
  

  1) Patients with recurrent or refractory B- or T-lineage lymphoblastic leukemia and lymphoma. Patients with LL must have either measurable or evaluable disease. 2) Patients with first or greater relapsed T-lineage ALL or LL and second or greater relapsed B-lineage ALL or LL are eligible. Patients with primary refractory disease with at least 2 prior induction attempts or first relapse refractory to at least one prior re-induction attempt are eligible. Patients with refractory disease, however, must not have received a standard 4-drug re-induction inclusive of a steroid, anthracycline, asparaginase and vincristine in combination (e.g., UKALLR3 or AALL01P2) as their most recent prior therapy but they may have received a re-induction regimen that contain some of these agents.
  

You may not be eligible for this study if the following are true:

• 1) Patients who are currently receiving other anti-cancer agents are not eligible [except patients receiving hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy]. 2) Patients who are currently receiving drugs that are strong inhibitors and/or inducers of CYP3A4 or sensitive CYP3A4 substrates and CYP3A4 substrates with a narrow therapeutic range are not eligible. Strong inducers or inhibitors of CYP3A4 are prohibited from 14 days prior to enrollment to the end of the study. See Appendix III for a list of agents.